**Name of Journal: *World Journal of Critical Care Medicine***

**ESPS Manuscript NO: 25105**

**Manuscript Type: Systematic Reviews**

**Predictive value of cytokines for developing complications after polytrauma**

Dekker ABE *et al.* Do cytokines predict polytrauma outcome

**Anne-Britt E Dekker, Pieta Krijnen, Inger B Schipper**

**Anne-Britt E Dekker, Pieta Krijnen, Inger B Schipper,** Department of Trauma Surgery, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

**Author contributions:** This study represents a great deal of effort, resources and dedication on the part of the authors in reviewing the literature and performing statistical analyses; all authors have participated in a material way to at least three of the following elements: Study design, gathered data, analysed data, initial draft, ensured accuracy of data; all authors read and approved the final manuscript.

**Conflict-of-interest statement:** All the authors declare that they have no competing interests.

**Data sharing statement:** The technical appendix including the full search strategy for this systematic review is available from the corresponding author at A.E.Dekker@lumc.nl. Since this study did not involve any biostatistics, no statistical code and dataset are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Mrs. Anne-Britt E Dekker,** Department of Trauma Surgery, Leiden University Medical Center, Postal Zone K6-R, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. a.e.dekker@lumc.nl

**Telephone:** +31-71-5261065

**Fax:** +31-71-5266750

**Received:** February 23, 2016

**Peer-review started:** February 25, 2016

**First decision:** March 24, 2016

**Revised:** April 8, 2016

**Accepted:** April 21, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM**: To investigate posttraumatic cytokine alterations and their value for predicting complications and mortality in polytraumatized patients.

**METHODS**: Studies on the use of specific cytokines to predict the development of complications and mortality were identified in MEDLINE, EMBASE, Web of Science and the Cochrane Library. Of included studies, relevant data were extracted and study quality was scored.

**RESULTS**: Forty-two studies published between 1988 and 2015 were identified, including 28 cohort studies and 14 “nested” case-control studies. Most studies investigated the cytokines interleukin (IL)-6, IL-8, IL-10 and tumor necrosis factor (TNF)-IL-6 seems related to muli-organ dysfunction syndrome, multi-organ failure (MOF) and mortality; IL-8 appears altered in acute respiratory distress syndrome, MOF and mortality; IL-10 alterations seem to precede sepsis and MOF; and TNF- seems related to MOF.

**CONCLUSION**: Cytokine secretion patterns appear to be different for patients developing complications when compared to patients with uneventful posttraumatic course. More research is needed to strengthen the evidence for clinical relevance of these cytokines.

**Key words:** Multiple trauma; Cytokine; Acute respiratory distress syndrome; Sepsis; Muli-organ dysfunction syndrome; Multi-organ failure

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Early identification of patients at risk for developing complications is one of the most challenging problems in the therapy of multiple injuries. Close monitoring of cytokine secretion patterns could give physicians an impression of the individual risk for development of complications. Further, physicians are directed to the appropriate prophylactic treatment, as well as optimal timing of surgical interventions, thereby reducing “second hits” with subsequent risks of development of sepsis and multiorgan failure. This article provides an overview of the results from literature concerning posttraumatic immune alterations leading to various complications and death.

Dekker ABE, Krijnen P, Schipper IB. Predictive value of cytokines for developing complications after polytrauma. *World J Crit Care Med* 2016; In press

**INTRODUCTION**

The term polytrauma is used to describe a combination of serious injuries in at least two different anatomical regions. Polytraumatized patients that survive the initial impact of trauma, are confronted with an enormous host defence reaction, which is associated with morbidity and mortality.Trauma initiates a local pro-inflammatory response, encompassing the activation of effector cells, complement cascade, coagulation system, cytokines, acute phase proteins and neuroendocrine mediators[1,2]. This sequence of events is part of the physiologic response to trauma, as it serves to initiate the healing process, prevents the host from additional injury and acts as a barrier against infection[3]. Yet extensive trauma can arouse a comprehensive systemic inflammatory state known as the systemic inflammatory response syndrome (SIRS). An overactivated pro-inflammatory reaction leads to progressive sequestration of leukocytes in vital organs, predisposing patients to the development of organ failure. In an attempt to mediate these deleterious effects, immunesuppressive mediators are released. This counter regulatory response syndrome (CARS) becomes active almost immediately after the onset of SIRS[4]. Despite dampening inflammation, CARS itself may have unfavorable effects as well, as it can induce an increased susceptibility to infections and sepsis[2]. The posttraumatic immunologic alterations of combined SIRS and CARS have been termed CHAOS (cardiovascular shock, homeostasis, apoptosis, organ dysfunctions and immune suppression)[5]. With an overwhelming initial traumatic insult, an overstimulated SIRS response initiates the chaos that results in early multiorgan failure, present within 72 h after injury[2,6]. A less severe initial insult may prime immune cells while eliciting a moderate inflammatory reaction. In this setting, a second insult (“hit”) may strengthen the inflammatory reaction towards immune suppression, predisposing the patient to sepsis[7,8].

Cytokines play a pivotal role in both the pro-inflammatory and the anti-inflammatory reaction to trauma[9,10]. The pro-inflammatory cytokine interleukin-6 (IL-6) is secreted by a wide range of cells including neutrophils, T- and B-lymphocytes and endothelial cells[8,11]. Release of IL-6 is enhanced after stimulation by micro-organisms and cytokines (TNF-, IL-1β), and liberated after tissue damage and infection. The biologic activity of IL-6 includes increased T- and B-cell activation and proliferation, differentiation of cytotoxic T cells and enhanced activity of natural killer (NK) cells[12]. In addition, IL-6 mediates the induction of the acute phase response and reduces apoptosis in neutrophil granulocytes[4,11]. Combined actions lead to an effective SIRS response early after trauma. The pro-inflammatory cytokine IL-8 is an endogenous chemoattractant. Monocytes, macrophages, neutrophils and endothelial cells secrete IL-8, and its release is enhanced after stimulation with IL-1, TNF-, C5a and LPS[9,13]. After activation, IL-8 induces expression of adhesion molecules on neutrophils and endothelial cells, which enables the migration of neutrophils to the site of production[4,9]. The anti-inflammatory cytokine IL-10 is primarily synthesized by CD4+ TH2 lymphocytes and, to a lesser extent, by B lymphocytes, monocytes and macrophages[8]. Activated IL-10 decreases the cytokine production of T­H1 cells, reduces antigen presentation of macrophages and subsequent proliferation of T-lymphocytes, and suppresses monocyte function[4,14,15]. These actions make IL-10 one of the most important mediators in the anti-inflammatory immune response. The pro-inflammatory cytokine TNF- is one of the first cytokines to be released after trauma. The cytokine is produced by monocytes, macrophages, lymphocytes and T lymphocytes. After secretion, TNF- increases endothelial cell permeability and adhesion properties, and activates macrophages, NK cells and lymphocytes. TNF- also induces the secretion of various cytokines [IL-6, -8, -10, interferon (IFN-γ)] and immunoglobulin production[7,12]. Release of excessive TNF- ultimately leads to accumulation of leukocytes in the injured tissues. Many of these cytokines attributed to the potential development of complications in polytrauma patient. Their exact causal role has not been detected yet.

Early identification of patients at risk for developing complications is one of the most challenging problems in the therapy of multiple injuries. Close monitoring of cytokine secretion patterns could give physicians an impression of the individual risk for development of complications. Further, physicians are directed to the appropriate prophylactic treatment, as well as optimal timing of surgical interventions, thereby reducing “second hits” with subsequent risks of development of sepsis and multiorgan failure. Previous studies have acknowledged the correlation between markers of inflammation and clinical condition after polytrauma. The aim of the current review was: (1) to summarize the available knowledge on specific cytokines that are involved in the posttraumatic immune alterations; and (2) to assess the value of cytokines for predicting the development of acute respiratory distress syndrome (ARDS), sepsis, multiorgan dysfunction syndrome (MODS), multiorgan failure (MOF) and mortality.

**MATERIALS AND METHODS**

The systematic review was performed in concordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement[16]. Due to heterogeneity across the studies in terms of patient population, study design and analytical techniques used, and the small amount of studies for each biomarker-complication combination, a meta-analysis was not feasible.

***Search strategy***

Studies addressing the relation between complications after multiple trauma and cytokine concentrations, were identified in the following databases: MEDLINE (1988 - 18 January 2014), Embase (1988 - 18 January 2014), Web of Science (1988 - 18 January 2014) and the Cochrane Library (to Issue 1, 2014). The search strategy was developed by an information specialist, and carried out using various combinations of the key words “multiple trauma”, “cytokines” and the complications “systemic inflammatory response sydrome (SIRS)”, “acute respiratory distress syndrome (ARDS)”, “sepsis”, “multiorgan dysfunction syndrome (MODS)”, “multiorgan failure (MOF)” and “mortality”. In addition, forward citation searches of selected studies and literature reviews were carried out. The initial search was not limited by language, publication date and type of publication. In February 2016, an additional literature search of the mentioned databases was carried out. One relevant new article was found.

***Outcome definitions***

Primary outcomes were the development of one or more of the following complications: (1) ARDS,determined in concordance with the American-European Consensus Conference (AECC) 1994 definitions[17]; (2) sepsis, diagnosed when SIRS (defined according to the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference 1992[18]) occurred in combination with a septic focus or positive blood culture; (3) MODS; and (4) MOF, in the included studies diagnosed based on different scoring systems[19-24]. The secondary outcome was mortality during a predetermined follow-up period of individual studies.

***Study selection***

Studies were scanned for eligibility based on title and abstract. Subsequently, eligibility of selected studies was assessed by retrieving the full text of the article. Inclusion criteria were prospective or retrospective cohort, case-control and cross-sectional studies including at least 10 adult multiple trauma patients (ISS ≥ 16). Excluded were articles in other language than English or German, animal studies and *ex vivo* studies, studies involving pediatric populations, case reports, review articles and letters/editorials. Studies not elaborating on the primary or secondary outcomes investigated in this review were also excluded. In addition, studies measuring cytokine concentrations in samples other than serum (*e.g*., wound exsudate, broncho-alveolar lavage fluid) were not eligible for inclusion, as local alterations in concentration may not reflect the systemic changes in the immune reaction.

***Data extraction***

The following data were extracted from included studies: title, study design, date of publication, size of study population, patient demographics, incidence of complications and mortality, follow-up period, type of cytokines studied, mean cytokine concentrations measured at specific moments during follow-up, and cut-off points with sensitivity and specificity. Data were extracted from figures when raw data were not available. In the case of duplicate publications, the most relevant or informative article was chosen.

***Quality assessment***

The quality of included studies was critically evaluated with the strengthening the reporting of observational studies in epidemiology (STROBE) statement[25].

***Biostatistics statement***

In this review of the literature no biostatistical methods were used. For this reason, no biomedical statistician was involved for statistical review.

**RESULTS**

***Identification of studies***

After exclusion of duplicate studies, the literature search yielded 730 potentially relevant articles. One hundred and thirty-eight articles passed the first screening and were retrieved for closer examination. Of the retrieved articles, 40 were eligible for study inclusion. The full text of six potentially relevant studies could not be obtained, which were therefore excluded from the analysis. Seven citations were found assessing reference lists of the included studies. One relevant article was encountered in the additional search carried out in 2016. The study selection procedure is outlined in Figure 1.

***Study characteristics***

The 42 included articles consisted of 28 cohort studies[3,13,26-51] and 14 “nested” case-control studies[11,14,52-63]. Two studies were retrospective[14,52]; the other 40 studies were prospective in study design. Studies were published between 1988 and 2015, and together included 5756 patients. The development of ARDS in relation to cytokine levels was investigated in seven studies; sixteen studies determined cytokine concentrations in sepsis; MODS development was assessed in ten studies; and eleven studies reported cytokine alterations in MOF. Twenty studies investigated the relation between cytokine concentrations and mortality. Only seven studies reported a cytokine cut-off value for the development of complications, five of which stated sensitivity (and specificity) for the cut-off value. Ten studies reported some kind of prediction value for the investigated cytokines (*i.e.*, odds ratio, area under the curve, sensitivity and specificity, 95% confidence interval and positive/negative predictive value). All included studies are listed in Table 1. The overall study quality according to the STROBE statement was good, with a median total score of 18 points (range 12-24), suggesting a low risk of bias.

***Value of main cytokine concentrations for predicting complications***

**IL-6:** (1) ARDS; Two studies[37,45] could not relate ARDS to IL-6 concentration alterations, whereas two other studies[48,51] found a positive correlation (Table 2); (2) Sepsis; Five studies[35,41,46,47,53] found an increased IL-6 production to be predictive for the development of sepsis, whereas five other studies[28,29,38,39,55] did not (Table 3); (3) MODS; All five prospective cohort studies[3,28,34,46,51] concluded that IL-6 is markedly increased in the early development of MODS (Table 4); and (4)MOF; Of the nine prospective studies, six[13,27,32,33,36,56] studies found a positive correlation between increased serum concentrations and development of MOF. Three[11,42,62] investigators demonstrated an elevated IL-6 in MOF patients, which was not predictive according to these studies (Table 5). Also, IL-6 tends to be higher in non-survivors (Table 6).

**IL-8:** (1)Two prospective cohort studies[37,48] reported a positive correlation between increased serum IL-8 concentrations and development of ARDS, whereas one[45] found no predictive value; (2) Two studies[38,55] reported that IL-8 was not significantly different between patients developing sepsis and those with an uneventful posttraumatic course; (3)One cohort study[3] found a higher IL-8 serum concentration in patients with MODS, which could however not predict the development of multiorgan dysfunction; and (4)Of the six included studies, four prospective studies[27,32,36,56] concluded that IL-8 is significantly higher in MOF. Two prospective studies[11,42] also found a significantly increased serum concentration, but concluded that this could not be translated into a predictive value for adverse outcome. Further, IL-8 concentrations seemed elevated in non-survivors.

**IL-10:** (1) Three studies, two prospective[54,57] and one retrospective[14], could not relate the serum IL-10 concentrations to the development of ARDS. One study[51] found Il-10 to be significantly higher in patients with ARDS; (2) Of the five reviewed studies, three prospective[29,50,54] and one retrospective study[14] found the IL-10 concentration to be predictive for the development of sepsis, whereas one prospective study[53] did not; (3)Two studies[51,54] reported IL-10 to be significantly elevated in patients with MODS, and two studies[3,57] could not find an association between the cytokine and development of MODS; and (4)According to five studies[13,32,33,36,50] the serum IL-10 concentration was significantly higher in MOF patients. One study showed no significant elevation[27].

**TNF-:** (1)Three studies found no relation between TNF- and development of ARDS[37,45,51]; (2)One study[55] concluded that concentrations were not related to development of sepsis, while one study[50] found significantly increased concentrations in septic patients; (3)Of the four studies reporting on TNF- concentrations after trauma, two studies[31,51] found TNF- to be related to the development of MODS, and two studies[3,57] could not relate serum concentrations to MODS; and (4)Four studies[13,32,50,62] showed that patients with MOF had significantly higher TNF- concentrations compared to patients with uneventful course, although Svoboda *et al*[62] found no predictive value for the cytokine.

**DISCUSSION**

Polytraumatized patients are at risk for the development of various complications, leading to considerable morbidity and mortality. Early identification of “high risk” patients could improve outcome after accidental injury, because physicians are directed to the appropriate treatment. Further, close monitoring of the immune response could direct physicians to the appropriate timing of surgical interventions, thereby reducing “second hits” with subsequent development of sepsis and organ failure. The aim of the present review was to summarize the knowledge on cytokines predicting the development of ARDS, sepsis, MODS, MOF and mortality. According to the investigated studies, some cytokines seem to predict specific complications: patients with ARDS seem to have higher IL-8 concentrations; IL-10 secretion seems increased in septic patients; and MODS/MOF development is preceded by an enhanced IL-6, IL-8, IL-10, and TNF- release. With respect to the other cytokines studied (IFN-γ, G-CSF, IL-1β, -2, -4, -11, -12, -17, -18, MIF, MIP-1β, eotaxin, IP-10), study results are either inconsistent, or the small amount of current evidence makes an objective conclusion for the present study impossible.

***IL-6***

Release of IL-6 is enhanced after stimulation by micro-organisms and cytokines (TNF-, IL-1β)[7,8]. It is liberated after tissue damage and infection. The relatively late release and long half-life of IL-6 renders the cytokine a convenient parameter for clinical monitoring of the immune response of individual patients. The conflicting results of the reviewed studies lead to the conclusion that IL-6 cannot be used as a marker for ARDS and sepsis; elevated IL-6 concentrations do appear to precede the development of MODS, MOF and mortality.In future, physicians might therefore use IL-6 as a predictor of MODS, MOF and mortality in polytraumatized patients.

***IL-8***

IL-8 induces expression of adhesion molecules, thereby enabling migration of neutrophils to the site of production[4,9]. Production of IL-8 takes place early in the inflammatory response and can persist for days or weeks[13]. According to the reviewed studies, IL-8 is higher in patients developing ARDS, MOF and in non-survivors. Of note, when IL-8 is used to investigate the development of ARDS, measuring local concentrations in bronchoalveolar lavage (BAL) fluid generally leads to earlier identification of patients at risk[64-67]. The causal relation between the chemotaxis IL-8 exerts on PMN’s, and subsequent autodestructive changes in remote organs leading to ARDS and MOF[64], likely explains the consistent results of included studies. In line with these results, IL-8 might be used to identify patients prone to develop ARDS and MOF. Such a predictive value could not be demonstrated for the development of sepsis and MODS.

***IL-10***

IL-10 decreases cytokine production of TH1 cells and reduces antigen presentation of macrophages and subsequent proliferation of T lymphocytes[14]. Release of high amounts of IL-10 occurs rapidly, generally within 60 min after trauma[54]. According to our study, an enhanced IL-10 secretion is related to the development of sepsis and MOF. Clearly, a vigorous anti-inflammatory IL-10 release makes the host susceptible to infections with subsequent sepsis and (sepsis-related) MOF. Therefore, IL-10 concentrations might direct physicians to the patients prone to develop sepsis and MOF. Concentrations of IL-10 could not be related to the development of ARDS, MODS and mortality.

***TNF-***

The pro-inflammatory cytokine TNF- is one of the first cytokines to be released after trauma[4]. Peak concentrations of TNF- can be observed within one to two hours after trauma. Previous studies have demonstrated a positive correlation between elevated TNF- and poor outcome[68-70]. However, as reported in this review, the elevation of TNF- could only be related to the development of MOF. This might be explained by the very short half-time of the cytokine (14-18 min), suggesting that peak concentrations early in the posttraumatic course have already returned to baseline by the time a septic event and subsequent organ failure is recognized[2,9,13].

***Other cytokines***

According to Cook *et al*[58], elevation of G-CSF significantly related to the development of hospital-acquired pneumonia. Wick *et al*[49] demonstrated that all patients with continuous decreased IL-12 levels died from septic multiorgan failure; comparable findings were demonstrated by Hensler *et al*[71]. Increased IL-12 production could, however, have unfavorable effects as well[72,73]. According to previous studies, IL-18 release is significantly correlated with sepsis, and its activation might be enhanced after infiltration of micro-organisms[74,75]. This effect could also be demonstrated by Mommsen *et al*[30]. Jastrow *et al*[32] determined a predictive value for several cytokines, among which IP-10, MIP-1βand eotaxin appear to be most accurate. More research has to be done before the value of these cytokines can be reviewed.

The principal limitation in this study was the heterogeneity across studies in terms of patient population, study design and statistical techniques used. Hence, meta-analysis of presented data could not be performed. Further, variations between patients in an individual study can result from differences in injury severity or injury pattern, diverse individual immunologic responses (gene polymorphisms), and general confounders such as age, sex, pre-existing diseases, number and amount of administrated therapeutic agents and secondary surgery. These aspects were not clearly outlined in most of the included studies. All these factors may alter the individual inflammatory response, and contribute to a low correlation between investigated cytokine and certain complication. Further, only a small amount of studies for each biomarker-complication combination was selected, due to the very specific research question. This made it difficult to draw clear conclusions from presented results. Also, some studies reported predictive values for the ratio of different cytokines. According to these studies, complications could be predicted more accurately when combining several cytokines in one prediction model. However, we could not include these findings in our results because of the small amount of studies investigating these specific ratios. Additionally, systemic concentrations of cytokines not necessarily reflect concentrations in end-organs. It might therefore be well possible that local concentrations of cytokines can more accurately predict the development of complications. Despite these concerns, the results presented in this review can be useful in the clinical appraisal of critically ill patients. For future studies on cytokines and polytrauma patients, we recommend the development of specific polytrauma protocols. Implementation of such protocols provides the possibility for meta-analysis in the future, as previously mentioned confounding factors would then be handled similarly. Important confounding factors that most studies did not elaborate on, include amount of resuscitation fluids administered, length of mechanical ventilation, need for nutritional support and secondary surgery. Monitoring cytokine secretion patterns without considering these factors, would give an unrealistic representation of posttraumatic immune alterations. Therefore, more research is needed to better understand the specific role of these factors in the individual immune response to trauma.

This article provides an overview of the results from literature concerning posttraumatic immune alterations leading to various complications and death. According to the current review, cytokine secretion patterns are different for patients developing complications, compared to patients with an uneventful posttraumatic course. Some of these cytokines, such as IL-6, IL-8 and IL-10, seem to be of value in the prediction of secondary deleterious effects after trauma. Close monitoring of these cytokines could direct physicians to the appropriate therapy of “high risk” patients, thereby reducing morbidity and mortality after polytrauma.

**COMMENTS**

***Background***

Severe trauma represents the most frequent cause of death in people below the age of 45. Early identification of patients at risk for developing complications is one of the most challenging problems in the treatment of multiple injuries. Close monitoring of cytokine secretion patterns may provide physicians with an impression of the patients’ risk for developing complications. Further, cytokine secretion patterns may pose an indication for the appropriate prophylactic treatment, as well as optimal timing of surgical interventions, thereby reducing the risk of sepsis and multiorgan failure. The aim of the current review was: (1) to summarize the available knowledge on specific cytokines that are involved in the posttraumatic immune alterations; and (2) to assess the value of cytokines for predicting the development of acute respiratory distress syndrome (ARDS), sepsis, muli-organ dysfunction syndrome (MODS), multi-organ failure (MOF) and mortality.

***Research frontiers***

Polytraumatized patients that survive the initial impact of trauma, are confronted with an enormous host defence reaction, which is associated with morbidity and mortality. Over the past 20-25 years, cytokines have gained attention in the understanding of the posttraumatic pathophysiological immune alterations. Cytokines play a pivotal role in the pro- and anti-inflammatory reaction to trauma, and are essential in the subsequent defence and repair mechanisms. As cytokines serve as messenger molecules in cell-to-cell communication, they are likely to play an important role in the development of posttraumatic complications such as sepsis and multi organ failure.

***Innovations and breakthroughs***

Previous studies have acknowledged the correlation between cytokine concentrations and patients’ clinical condition after polytrauma. Yet, specific predictors for the development of posttraumatic complications have not been identified. The available literature concerning the relation between cytokine concentrations and development of posttraumatic complications was systematically reviewed by the authors, and the data were extracted using a standardized collection tool.

***Applications***

This review suggests that interleukin (IL)-6, IL-8 and IL-10 are of value in the prediction of secondary deleterious effects after trauma. Close monitoring of these cytokines could direct physicians to the appropriate therapy of “high risk” patients, thereby reducing morbidity and mortality after polytrauma.

***Terminology***

SIRS: Systemic inflammatory response syndrome, defined according to the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference 1992; ARDS: Acute respiratory distress syndrome,determined in concordance with the American-European Consensus Conference (AECC) 1994 definitions;Sepsis:Diagnosed when SIRS occurs in combination with a septic focus or positive blood culture; MODS and MOF: Multi-organ dysfunction syndrome/multi-organ failure, diagnosed based on different scoring systems.

***Peer-review***

This is an excellent literature analysis on an important issue. The paper was very well-structured and written.

**REFERENCES**

1 **Flohé S**, Flohé SB, Schade FU, Waydhas C. Immune response of severely injured patients--influence of surgical intervention and therapeutic impact. *Langenbecks Arch Surg* 2007; **392**: 639-648 [PMID: 17605036 DOI: 10.1007/s00423-007-0203-4]

2 **Dewar D**, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. *Injury* 2009; **40**: 912-918 [PMID: 19541301 DOI: 10.1016/j.injury.2009.05.024]

3 **Frink M**, van Griensven M, Kobbe P, Brin T, Zeckey C, Vaske B, Krettek C, Hildebrand F. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. *Scand J Trauma Resusc Emerg Med* 2009; **17**: 49 [PMID: 19781105 DOI: 10.1186/1757-7241-17-49]

4 **Hietbrink F**, Koenderman L, Rijkers G, Leenen L. Trauma: the role of the innate immune system. *World J Emerg Surg* 2006; **1**: 15 [PMID: 16759367 DOI: 10.1186/1749-7922-1-15]

5 **Keel M**, Trentz O. Pathophysiology of polytrauma. *Injury* 2005; **36**: 691-709 [PMID: 15910820 DOI: 10.1016/j.injury.2004.12.037]

6 **Tschoeke SK**, Ertel W. Immunoparalysis after multiple trauma. *Injury* 2007; **38**: 1346-1357 [PMID: 18048039 DOI: 10.1016/j.injury.2007.08.041]

7 **Ciriello V**, Gudipati S, Stavrou PZ, Kanakaris NK, Bellamy MC, Giannoudis PV. Biomarkers predicting sepsis in polytrauma patients: Current evidence. *Injury* 2013; **44**: 1680-1692 [PMID: 24119650 DOI: 10.1016/j.injury.2013.09.024]

8 **Giannoudis PV**, Hildebrand F, Pape HC. Inflammatory serum markers in patients with multiple trauma. Can they predict outcome? *J Bone Joint Surg Br* 2004; **86**: 313-323 [PMID: 15125116 DOI: 10.1302/0301-620X.86B3.15035]

9 **Hildebrand F**, Pape HC, Krettek C. [The importance of cytokines in the posttraumatic inflammatory reaction]. *Unfallchirurg* 2005; **108**: 793-794, 793-794 [PMID: 16175346 DOI: 10.1007/s00113-005-1005-1]

10 **Sears BW**, Stover MD, Callaci J. Pathoanatomy and clinical correlates of the immunoinflammatory response following orthopaedic trauma. *J Am Acad Orthop Surg* 2009; **17**: 255-265 [PMID: 19307674 DOI: 10.5435/00124635-200904000-00006]

11 **Frank J**, Maier M, Koenig J, Rose S, Bouma M, Buurman WA, Marzi I. Circulating inflammatory and metabolic parameters to predict organ failure after multiple trauma. *Eur J Trauma* 2002; **28**: 333-339 [DOI: 10.1007/s00068-002-1263-3]

12 **DeLong WG**, Born CT. Cytokines in patients with polytrauma. *Clin Orthop Relat Res* 2004: 57-65 [PMID: 15187834 DOI: 10.1097/01.blo.0000130840.64528.1e]

13 **Lendemans S**, Kreuzfelder E, Waydhas C, Nast-Kolb D, Flohé S. [Clinical course and prognostic significance of immunological and functional parameters after severe trauma]. *Unfallchirurg* 2004; **107**: 203-210 [PMID: 14999368 DOI: 10.1007/s00113-004-0729-7]

14 **Sherry RM**, Cue JI, Goddard JK, Parramore JB, DiPiro JT. Interleukin-10 is associated with the development of sepsis in trauma patients. *J Trauma* 1996; **40**: 613-616; discussion 613-616 [PMID: 8614042 DOI: 10.1097/00005373-199604000-00016]

15 **Keel M**, Schregenberger N, Steckholzer U, Ungethüm U, Kenney J, Trentz O, Ertel W. Endotoxin tolerance after severe injury and its regulatory mechanisms. *J Trauma* 1996; **41**: 430-437; discussion 430-437 [PMID: 8810959 DOI: 10.1097/00005373-199609000-00008]

16 **Moher D**, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; **339**: b2535 [PMID: 19622551 DOI: 10.1136/bmj.b2535]

17 **Bernard GR**, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994; **149**: 818-824 [PMID: 7509706 DOI: 10.1007/BF01704707]

18 **Bone RC**, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992; **101**: 1644-1655 [PMID: 1303622 DOI: 10.1378/chest.101.6.1644]

19 **Marshall JC**, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med* 1995; **23**: 1638-1652 [PMID: 7587228 DOI: 10.1097/00003246-199510000-00007]

20 **Goris RJ**, te Boekhorst TP, Nuytinck JK, Gimbrère JS. Multiple-organ failure. Generalized autodestructive inflammation? *Arch Surg* 1985; **120**: 1109-1115 [PMID: 4038052 DOI: 10.1001/archsurg.1985.01390340007001]

21 **Sauaia A**, Moore FA, Moore EE, Norris JM, Lezotte DC, Hamman RF. Multiple organ failure can be predicted as early as 12 hours after injury. *J Trauma* 1998; **45**: 291-301; discussion 301-3 [PMID: 9715186 DOI: 10.1097/00005373-199808000-00014]

22 **Moore FA**, Moore EE, Poggetti R, McAnena OJ, Peterson VM, Abernathy CM, Parsons PE. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. *J Trauma* 1991; **31**: 629-636; discussion 636-638 [PMID: 2030509 DOI: 10.1097/00005373-199105000-00006]

23 **Lefering R**, Goris RJ, van Nieuwenhoven EJ, Neugebauer E. Revision of the multiple organ failure score. *Langenbecks Arch Surg* 2002; **387**: 14-20 [PMID: 11981679 DOI: 10.1007/s00423-001-0269-3]

24 **Grotz M**, von Griensven M, Stalp M, Kaufmann U, Hildebrand F, Pape HC. [Scoring multiple organ failure after severe trauma. Comparison of the Goris, Marshall and Moore scores]. *Chirurg* 2001; **72**: 723-730 [PMID: 11469095 DOI: 10.1007/s001040170130]

25 **von Elm E**, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; **61**: 344-349 [PMID: 18313558 DOI: 10.1016/j.jclinepi.2007.11.008]

26 **Dresing K**, Armstrong VW, Leip CL, Streit F, Burchardi H, Stürmer KM, Oellerich M. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. *Clin Biochem* 2007; **40**: 1194-1200 [PMID: 17707362 DOI: 10.1016/j.clinbiochem.2007.06.013]

27 **Maier B**, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. *Shock* 2007; **28**: 668-674 [PMID: 18092384 DOI: 10.1097/shk.0b013e318123e64e]

28 **Haasper C**, Kalmbach M, Dikos GD, Meller R, Müller C, Krettek C, Hildebrand F, Frink M. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. *Technol Health Care* 2010; **18**: 89-100 [PMID: 20495248]

29 **Lausević Z**, Vuković G, Stojimirović B, Trbojević-Stanković J, Resanović V, Lausevic M. Kinetics of C-reactive protein, interleukin-6 and -10, and phospholipase A2-II in severely traumatized septic patients. *Vojnosanit Pregl* 2010; **67**: 893-897 [PMID: 21268514 DOI: 10.2298/VSP1011893L]

30 **Mommsen P**, Frink M, Pape HC, van Griensven M, Probst C, Gaulke R, Krettek C, Hildebrand F. Elevated systemic IL-18 and neopterin levels are associated with posttraumatic complications among patients with multiple injuries: a prospective cohort study. *Injury* 2009; **40**: 528-534 [PMID: 19054512 DOI: 10.1016/j.injury.2008.08.007]

31 **Hayakawa M**, Katabami K, Wada T, Minami Y, Sugano M, Shimojima H, Kubota N, Uegaki S, Sawamura A, Gando S. Imbalance between macrophage migration inhibitory factor and cortisol induces multiple organ dysfunction in patients with blunt trauma. *Inflammation* 2011; **34**: 193-197 [PMID: 20499270 DOI: 10.1007/s10753-010-9223-2]

32 **Jastrow KM**, Gonzalez EA, McGuire MF, Suliburk JW, Kozar RA, Iyengar S, Motschall DA, McKinley BA, Moore FA, Mercer DW. Early cytokine production risk stratifies trauma patients for multiple organ failure. *J Am Coll Surg* 2009; **209**: 320-331 [PMID: 19717036 DOI: 10.1016/j.jamcollsurg.2009.05.002]

33 **Lausevic Z**, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. *Can J Surg* 2008; **51**: 97-102 [PMID: 18377749]

34 **Cuschieri J**, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O'Keefe G, Sperry J, Remick D, Tompkins R, Maier RV. Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. *Shock* 2010; **34**: 346-351 [PMID: 20844410 DOI: 10.1097/SHK.0b013e3181de687]

35 **Billeter A**, Turina M, Seifert B, Mica L, Stocker R, Keel M. Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. *World J Surg* 2009; **33**: 558-566 [PMID: 19148699 DOI: 10.1007/s00268-008-9896-y]

36 **Bogner V**, Keil L, Kanz KG, Kirchhoff C, Leidel BA, Mutschler W, Biberthaler P. Very early posttraumatic serum alterations are significantly associated to initial massive RBC substitution, injury severity, multiple organ failure and adverse clinical outcome in multiple injured patients. *Eur J Med Res* 2009; **14**: 284-291 [PMID: 19661010 DOI: 10.1186/2047-783X-14-7-284]

37 **Donnelly TJ**, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. *Crit Care Med* 1994; **22**: 768-776 [PMID: 8181284 DOI: 10.1097/00003246-199405000-00010]

38 **Egger G**, Aigner R, Glasner A, Hofer HP, Mitterhammer H, Zelzer S. Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: comparison with various inflammation parameters. *Intensive Care Med* 2004; **30**: 331-334 [PMID: 14727016 DOI: 10.1007/s00134-003-2111-6]

39 **Flores JM**, Jiménez PI, Rincón MD, Márquez JA, Navarro H, Arteta D, Murillo F. Early risk factors for sepsis in patients with severe blunt trauma. *Injury* 2001; **32**: 5-12 [PMID: 11164394 DOI: 10.1016/S0020-1383(00)00103-0]

40 **Gebhard F**, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Brückner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? *Arch Surg* 2000; **135**: 291-295 [PMID: 10722030 DOI: 10.1001/archsurg.135.3.291]

41 **Keel M**, Härter L, Reding T, Sun LK, Hersberger M, Seifert B, Bimmler D, Graf R. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. *Crit Care Med* 2009; **37**: 1642-1648 [PMID: 19325491 DOI: 10.1097/CCM.0b013e31819da7d6]

42 **Law MM**, Cryer HG, Abraham E. Elevated levels of soluble ICAM-1 correlate with the development of multiple organ failure in severely injured trauma patients. *J Trauma* 1994; **37**: 100-109; discussion 100-109 [PMID: 7913140 DOI: 10.1097/00005373-199407000-00017]

43 **Liener UC**, Brückner UB, Knöferl MW, Steinbach G, Kinzl L, Gebhard F. Chemokine activation within 24 hours after blunt accident trauma. *Shock* 2002; **17**: 169-172 [PMID: 11900333 DOI: 10.1097/00024382-200203000-00002]

44 **Livingston DH**, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. *Arch Surg* 1988; **123**: 1309-1312 [PMID: 3140765 DOI: 10.1001/archsurg.1988.01400350023002]

45 **Meade P**, Shoemaker WC, Donnelly TJ, Abraham E, Jagels MA, Cryer HG, Hugli TE, Bishop MH, Wo CC. Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury. *J Trauma* 1994; **36**: 651-657 [PMID: 8189465 DOI: 10.1097/00005373-199405000-00009]

46 **Oberholzer A**, Keel M, Zellweger R, Steckholzer U, Trentz O, Ertel W. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. *J Trauma* 2000; **48**: 932-937 [PMID: 10823539 DOI: 10.1097/00005373-200005000-00019]

47 **Paunel-Görgülü A**, Flohé S, Scholz M, Windolf J, Lögters T. Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. *Crit Care* 2011; **15**: R20 [PMID: 21232130 DOI: 10.1186/cc9965]

48 **Raymondos K**, Martin MU, Schmudlach T, Baus S, Weilbach C, Welte T, Krettek C, Frink M, Hildebrand F. Early alveolar and systemic mediator release in patients at different risks for ARDS after multiple trauma. *Injury* 2012; **43**: 189-195 [PMID: 21703617 DOI: 10.1016/j.injury.2011.05.034]

49 **Wick M**, Kollig E, Walz M, Muhr G, Köller M. [Does liberation of interleukin-12 correlate with the clinical course of polytraumatized patients?]. *Chirurg* 2000; **71**: 1126-1131 [PMID: 11043131 DOI: 10.1007/s001040051189]

50 **Menges T**, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R, Wollbrueck M, Hempelmann G. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. *Crit Care Med* 1999; **27**: 733-740 [PMID: 10321662 DOI: 10.1097/00003246-199904000-00026]

51 **Sousa A**, Raposo F, Fonseca S, Valente L, Duarte F, Gonçalves M, Tuna D, Paiva JA. Measurement of cytokines and adhesion molecules in the first 72 hours after severe trauma: association with severity and outcome. *Dis Markers* 2015; **2015**: 747036 [PMID: 25861153 DOI: 10.1155/2015/747036]

52 **Heizmann O**, Koeller M, Muhr G, Oertli D, Schinkel C. Th1- and Th2-type cytokines in plasma after major trauma. *J Trauma* 2008; **65**: 1374-1378 [PMID: 19077629 DOI: 10.1097/TA.0b013e31818b257d]

53 **Gouel-Chéron A**, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. *PLoS One* 2012; **7**: e33095 [PMID: 22431998 DOI: 10.1371/journal.pone.0033095]

54 **Neidhardt R**, Keel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, Ertel W. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. *J Trauma* 1997; **42**: 863-870; discussion 870-871 [PMID: 9191668 DOI: 10.1097/00005373-199705000-00017]

55 **Giamarellos-Bourboulis EJ**, Mouktaroudi M, Tsaganos T, Koutoukas P, Spyridaki E, Pelekanou A, Kotzampassi K. Evidence for the participation of soluble triggering receptor expressed on myeloid cells-1 in the systemic inflammatory response syndrome after multiple trauma. *J Trauma* 2008; **65**: 1385-1390 [PMID: 19077631 DOI: 10.1097/TA.0b013e31814699cc]

56 **Partrick DA**, Moore FA, Moore EE, Biffl WL, Sauaia A, Barnett CC. Jack A. Barney Resident Research Award winner. The inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure. *Am J Surg* 1996; **172**: 425-429; discussed 425-429 [PMID: 8942538 DOI: 10.1016/S0002-9610(96)00252-8]

57 **Spielmann S**, Kerner T, Ahlers O, Keh D, Gerlach M, Gerlach H. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. *Acta Anaesthesiol Scand* 2001; **45**: 364-370 [PMID: 11207475 DOI: 10.1034/j.1399-6576.2001.045003364.x]

58 **Cook KM**, Sifri ZC, Baranski GM, Mohr AM, Livingston DH. The role of plasma granulocyte colony stimulating factor and bone marrow dysfunction after severe trauma. *J Am Coll Surg* 2013; **216**: 57-64 [PMID: 23063381 DOI: 10.1016/j.jamcollsurg.2012.08.028]

59 **Frangen TM**, Bogdanski D, Schinkel C, Roetman B, Kälicke T, Muhr G, Köller M. Systemic IL-17 after severe injuries. *Shock* 2008; **29**: 462-467 [PMID: 17909455]

60 **Roetman B**, Schinkel C, Wick M, Frangen T, Muhr G, Köller M. Elevated systemic interleukin-18 in multiple injured patients is not related to clinical outcome. *J Interferon Cytokine Res* 2008; **28**: 741-747 [PMID: 18937548 DOI: 10.1089/jir.2008.0029]

61 **Schinkel C**, Wick M, Muhr G, Köller M. Analysis of systemic interleukin-11 after major trauma. *Shock* 2005; **23**: 30-34 [PMID: 15614128 DOI: 10.1097/01.shk.0000148057.20010.cf]

62 **Svoboda P**, Kantorová I, Ochmann J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. *J Trauma* 1994; **36**: 336-340 [PMID: 8145312 DOI: 10.1097/00005373-199403000-00009]

63 **Yagmur Y**, Ozturk H, Unaldi M, Gedik E. Relation between severity of injury and the early activation of interleukins in multiple-injured patients. *Eur Surg Res* 2005; **37**: 360-364 [PMID: 16465061 DOI: 10.1159/000090337]

64 **Muehlstedt SG**, Lyte M, Rodriguez JL. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. *Shock* 2002; **17**: 443-450 [PMID: 12069178 DOI: 10.1097/00024382-200206000-00001]

65 **Donnelly SC**, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, Haslett C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet* 1993; **341**: 643-647 [PMID: 8095568 DOI: 10.1016/0140-6736(93)90416-E]

66 **Aggarwal A**, Baker CS, Evans TW, Haslam PL. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. *Eur Respir J* 2000; **15**: 895-901 [PMID: 10853855 DOI: 10.1034/j.1399-3003.2000.15e14.x]

67 **Suter PM**, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. *Am Rev Respir Dis* 1992; **145**: 1016-1022 [PMID: 1586041 DOI: 10.1164/ajrccm/145.5.1016]

68 **Strieter RM**, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. *Crit Care Med* 1993; **21**: S447-S463 [PMID: 8403983 DOI: 10.1097/00003246-199310001-00006]

69 **Ozturk H**, Yagmur Y, Ozturk H. The prognostic importance of serum IL-1beta, IL-6, IL-8 and TNF-alpha levels compared to trauma scoring systems for early mortality in children with blunt trauma. *Pediatr Surg Int* 2008; **24**: 235-239 [PMID: 18060414 DOI: 10.1007/s00383-007-2083-7]

70 **Zedler S**, Faist E. The impact of endogenous triggers on trauma-associated inflammation. *Curr Opin Crit Care* 2006; **12**: 595-601 [PMID: 17077693 DOI: 10.1097/MCC.0b013e3280106806]

71 **Hensler T**, Heidecke CD, Hecker H, Heeg K, Bartels H, Zantl N, Wagner H, Siewert JR, Holzmann B. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. *J Immunol* 1998; **161**: 2655-2659 [PMID: 9725269]

72 **Car BD**, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, Huang S, Aguet M, Anderson TD, Ryffel B. Role of interferon-gamma in interleukin 12-induced pathology in mice. *Am J Pathol* 1995; **147**: 1693-1707 [PMID: 7495294]

73 **Ryffel B**. Interleukin-12: role of interferon-gamma in IL-12 adverse effects. *Clin Immunol Immunopathol* 1997; **83**: 18-20 [PMID: 9073529 DOI: 10.1006/clin.1996.4306]

74 **Emmanuilidis K**, Weighardt H, Matevossian E, Heidecke CD, Ulm K, Bartels H, Siewert JR, Holzmann B. Differential regulation of systemic IL-18 and IL-12 release during postoperative sepsis: high serum IL-18 as an early predictive indicator of lethal outcome. *Shock* 2002; **18**: 301-305 [PMID: 12392271 DOI: 10.1097/00024382-200210000-00002]

75 **Oberholzer A**, Steckholzer U, Kurimoto M, Trentz O, Ertel W. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. *Shock* 2001; **16**: 411-414 [PMID: 11770036 DOI: 10.1097/00024382-200116060-00001]

**P-Reviewer:** Cotogni P, Wang Y **S-Editor:** Ji FF **L-Editor: E-Editor:**



**Figure 1 Results of the stepwise literature review procedure.**

**Table 1 Overview of included studies, the studied cytokines and the outcome parameters (acute respiratory distress syndrome, sepsis, muli-organ dysfunction syndrome, multi-organ failure, mortality)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Ref.** | **Year**  | **Design** | **No pts.****(control)** | **Cytokines** | **ARDS****(%)** | **Sepsis****(%)** | **MODS****(%)** | **MOF****(%)** | **Mortality****(%)** |
| 1 | Billeter A[35] | 2009 | P-coh | 1032 | IL-6 |  |  |  |  | 10% |
| 2 | Bogner V[36] | 2009 | P-coh | 58 | IL-6, -8, -10 |  |  |  | 74% | 19% |
| 3 | Cook KM[58] | 2013 | P-cc | 83 (18) | G-CSF |  | 7% |  |  | 7% |
| 4 | Cuschieri J[34] | 2010 | P-coh | 152 | IL-6 |  |  | 37% |  | 5% |
| 5 | Donnelly TJ[37] | 1994 | P-coh | 15 | IL-6, -8, -1; TNF- | 49% |  |  |  | 33% |
| 6 | Dresing K[26] | 2004 | P-coh | 30 | IL-6; TNF- |  |  | 13% |  | 19% |
| 7 | Egger G[38] | 2004 | P-coh | 26 | IL-6, -8 |  | 35% |  |  |  |
| 8 | Flores JM[39] | 2001 | P-coh | 43 | IL-6 |  | 49% |  |  | 16% |
| 9 | Frangen TM[59] | 2008 | P-cc | 71 (25) | IL-17, -6 |  |  |  |  | 22% |
| 10 | Frank J[11] | 2002 | P-cc | 77 (15) | IL-6, -8 |  |  |  |  | 9% |
| 11 | Frink M[3] | 2009 | P-coh | 143 | IL-1β, -6, -8, -10; TNF- |  | 29% | 17% |  | 15% |
| 12 | Gebhard F[40] | 2000 | P-coh | 94 | IL-6 |  |  |  |  | 19% |
| 13 | Giamarellos-Bourboulis EJ[55] | 2008 | P-cc | 69 (10) | IL-6, -8; TNF-, IFN-γ |  | 62% |  |  | 35% |
| 14 | Gouel-Cheron A[53] | 2012 | P-cc | 100 (18) | IL-6, -10 |  | 37% |  |  | 5% |
| 15 | Haasper C[28] | 2010 | P-coh | 94 | IL-6 |  | 16% | 22% |  | 13% |
| 16 | Hayakawa M[31] | 2011 | P-coh | 45 | TNF- |  |  | 53% |  | 25% |
| 17 | Heizmann O[52] | 2008 | R-cc | 195 (10) | IL-2, -4, -10, -11, -12, -18; IFN-γ |  |  |  |  | 19% |
| 18 | Jastrow KM[32] | 2009 | P-coh | 48 | IL-6, -8, -10, -1β, -2, -4, -12; TNF-  |  |  |  | 23% | 17% |
| 19 | Keel M[41] | 2009 | P-coh | 83 | IL-6 |  | 40% |  |  | 12% |
| 20 | Lausevic Z[33] | 2008 | P-coh | 65 | IL-6, -10 |  | 62% |  | 55% | 51% |
| 21 | Lausevic Z[29] | 2010 | P-coh | 65 | IL-6, -10 |  | 63% |  |  | 51% |
| 22 | Law M[42] | 1994 | P-coh | 13 | IL-6, -8; TNF- |  |  |  | 46% | 23% |
| 23 | Lendemans S[13] | 2004 | P-coh | 16 | IL-6, -10; TNF- |  |  |  | 56% |  |
| 24 | Liener UC[43] | 2002 | P-coh | 94 | IL-8 | 0% | 0% |  | 0% | 19% |
| 25 | Livingston DH[44] | 1988 | P-coh | 20 | IFN-γ |  | 30% |  |  | 15% |
| 26 | Maier B[27] | 2007 | P-coh | 251 | IL-6, -8, -10 |  |  |  | 34% | 12% |
| 27 | Meade P[45] | 1994 | P-coh | 25 | IL-6, -8; TNF- | 36% |  |  |  |  |
| 28 | Menges T[50] | 1999 | P-coh | 68 | IL-10, -1; TNF- |  | 25% |  | 25% | 1% |
| 29 | Mommsen P[30] | 2009 | P-coh | 55 | IL-18 |  | 42% | 13% |  | 13% |
| 30 | Neidhardt R[54] | 1997 | P-cc | 417 (137) | IL-10 | 5% | 11% | 22% |  | 22% |
| 31 | Oberholzer A[46] | 2000 | P-coh | 1276 | IL-6, IL-10 |  | 14% | 40% |  | 7% |
| 32 | Partrick DA[56] | 1996 | P-cc | 27 (6) | IL-6, -8 |  |  |  | 33% | 7% |
| 33 | Paunel-Görgülü A[47] | 2011 | P-coh | 47 (17) | IL-6 |  | 38% |  |  | 11% |
| 34 | Raymondos K[48] | 2012 | P-coh | 24 | IL-6, -8, -1β, TNF- | 29% |  |  |  | 4% |
| 35 | Roetman B[60] | 2008 | P-cc | 229 (110) | IL-18, -4; IFN-γ |  |  |  |  | 16% |
| 36 | Schinkel C[61] | 2005 | P-cc | 216 (110) | IL-11 |  |  |  | 4% | 16% |
| 37 | Sherry RM[14] | 1996 | R-cc | 66 (10) | IL-10 | 8% | 39% |  |  | 2% |
| 38 | Sousa A[51] | 2015 | P-coh | 99 | IL-6, -10; TNF- | 19% |  | 34% |  | 28% |
| 38 | Spielmann S[57] | 2001 | P-cc | 47 (15) | TNF- | 11% | 30% | 51% |  | 23% |
| 39 | Svoboda P[62] | 1994 | P-cc | 42 (12) | IL-1β, -2, -6; TNF- |  |  |  | 33% | 26% |
| 40 | Wick M[49] | 2000 | P-coh | 37 | IL-12 |  |  | 11% |  | 16% |
| 41 | Yagmur Y[63] | 2005 | P-cc | 99 (10) | IL-1, -2, -6, -8; TNF- |  |  |  |  | 17% |

P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor; IFN: Interferon.

**Table 2 Value of cytokine concentrations for predicting acute respiratory distress syndrome**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Year** | **Design** | **No pts.** | **ARDS*****n* (%)** | **Predicts****ARDS** | **Results**  |
| IL-6 |  |  |  |  |  |  |
|  Donnelly, TJ | 1994 | P-coh | 15 | 7 (49%) | N | (IL-6) is not significantly different in ARDS |
|  Meade, P | 1994 | P-coh | 25 | 9 (36%) | N  | (IL-6) is higher in patients with ARDS after onset of symptoms; does not predict development of ARDS |
|  Raymondos, K | 2012 | P-coh | 24 | 7 (29%) | Y | (IL-6) is significantly higher in patients at high risk for ARDS |
|  Sousa, A | 2015 | P-coh | 99 | 19 (19%) | Y | (IL-6) is significantly higher at 72 h post injury |
| IL-8 |  |  |  |  |  |  |
|  Donnelly, TJ | 1994 | P-coh | 15 | 7 (49%) | Y | (IL-8) is significantly higher in patients with ARDS, starting at 16 h post injury |
|  Meade, P | 1994 | P-coh | 25 | 9 (36%) | N | (IL-8) is higher in patients with ARDS after onset of symptoms; does not predict development of ARDS |
|  Raymondos, K | 2012 | P-coh | 24 | 7 (29%) | Y | (IL-8) is significantly higher in patients at high risk for ARDS |
| IL-10 |  |  |  |  |  |  |
|  Neidhardt, R | 1997 | P-cc | 417  | 19 (5%) | N | (IL-10) is not related to the development of ARDS |
|  Sherry, RM | 1996 | R-cc | 66 | 5 (8%) | N | (IL-10) is not related to the development of ARDS |
|  Sousa, A  | 2015 | P-coh | 99 | 19 (19%) | Y | (IL-10) is significantly higher in patients with ARDS upon admission, at 24 + 48 + 72 h post injury |
|  Spielmann, S | 2001 | P-cc | 47 | 5 (11%) | N | (IL-10) is not related to the development of ARDS |
| TNF- |  |  |  |  |  |  |
|  Donnelly, TJ | 1994 | P-coh  | 15  | 7 (49%) | N | (TNF-) below detection limit |
|  Meade, P  | 1994 | P-coh  | 25 | 9 (36%) | N | (TNF-) below detection limit |
|  Sousa, A  | 2015 | P-coh | 99 | 19 (19%) | N | (TNF-) is not related to the development of ARDS |
| IL-1β |  |  |  |  |  |  |
|  Donnelly, TJ  | 1994 | P-coh  | 15  | 7 (49%) | N | (IL-1β) below detection limit |
|  Meade, P | 1994 | P-coh | 25 | 9 (36%) | N | (IL-1β) below detection limit |

P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor.

**Table 3 Value of cytokine concentrations for predicting sepsis**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Year** | **Design** | **No pts.** | **Sepsis*****n* (%)** | **Diagnostic tests** | **Predicts sepsis** | **Results**  |
| IL-6 |  |  |  |  |  |  |  |
|  Billeter, A | 2009 | P-coh | 1032 |  |  | Y | (IL-6) is significantly higher in sepsis between days 3-7 |
|  Egger, G | 2004 | P-coh | 26 | 9 (35%) |  | N | (IL-6) is significantly higher in sepsis before clinical manifestations; does not predict sepsis |
|  Flores, JM  | 2001 | P-coh | 43 | 21 (49%) |  | N | (IL-6) is not significantly altered in sepsis |
|  Giamarellos-Bourboulis, EJ | 2008 | P-cc | 69 | 43 (62%) | ROC AUC 0.500 (95%CI: 0.304-0.696, *P* > 0.05) | N | (IL-6) is not related to the development of sepsis |
|  Gouel-Geron, A | 2012 | P-cc | 100  | 37 (37%) | > 67.1 pg/mL: Sensitivity 85%; specificity 73% | Y | (IL-6) > 67.1 pg/mL is predictive for sepsis on days 1 + 2 (OR 10.9) |
|  Haasper, C | 2010 | P-coh | 94 | 15 (16%) |  | N | (IL-6) is not significantly different in sepsis |
|  Keel, M  | 2009 | P-coh | 83 | 33 (40%) |  | Y | (IL-6) is significantly higher in sepsis on days 5 + 14 |
|  Lausevic, C | 2010 | P-coh | 65 | 41 (63%) |  | N | (IL-6) is not predictive for sepsis |
|  Oberholzer, A | 2000 | P-coh | 1276 | 179 (14%) |  | Y | (IL-6) is significantly higher in septic patients |
|  Paunel-Görgülü, A | 2011 | P-coh | 47 | 18 (38%) | AUC ROC 0.79 (day 5 post injury) | Y | (IL-6) is significantly elevated on days 5 + 9 in sepsis |
| IL-8 |  |  |  |  |  |  |  |
|  Egger G | 2004 | P-coh | 26 | 9 (35%) |  | N | (IL-8) is not significantly altered in sepsis |
|  Giamarellos-Bourboulis, EJ | 2008 | P-cc | 69  | 43 (62%) | AUC ROC 0.453 (95%CI: 0.254-0.652, *P* > 0.05) | N | (IL-8) is not predictive for sepsis |
| IL-10 |  |  |  |  |  |  |  |
|  Gouel-Geron, A | 2012 | P-cc | 100 | 37 (37%) |  | N | (IL-10) is not related to the development of sepsis |
|  Lausevic, C | 2010 | P-coh | 65 | 41 (63%) |  | Y | (IL-10) is significantly lower in sepsis on days 1 + 2 |
|  Menges T | 1999 | P-coh | 68 | 17 (25%) |  | Y | (IL-10) is significantly higher in sepsis and MOF after 6 d |
|  Neidhardt, R | 1997 | P-cc | 417  | 45 (11%) |  | Y | (IL-10) is significantly higher in sepsis on days 1 + 3 + 5 + 7 + 10 + 14 + 21 |
|  Sherry, RM | 1996 | R-cc | 66  | 26 (39%) |  | Y | (IL-10) is significantly higher in sepsis |
| TNF- |  |  |  |  |  |  |  |
|  Giamarellos-Bourboulis, EJ | 2008 | P-cc | 69  | 43 (62%) | AUC ROC0.466 (95%CI: 0.274-0.657, *P* > 0.05) | N | (TNF-) is not related to the development of sepsis |
|  Menges, T | 1999 | P-coh | 68 | 17 (25%) |  | Y | (TNF-) is significantly higher in sepsis and MOF after 8 d |
| IFN-γ |  |  |  |  |  |  |  |
|  Giamarellos-Bourboulis, EJ | 2008 | P-cc | 69  | 43 (62%) |  | N | (IFN-γ) below detection limit |
|  Livingston, DH | 1988 | P-coh | 20 | 6 (30%) |  | Y | (IFN-γ) is markedly lower in sepsis after 14 d |
| G-CSF |  |  |  |  |  |  |  |
|  Cook, KM | 2013 | P-cc | 83  | 6 (7%) |  | Y | (G-CSF) > 500 pg/mL is significantly associated with sepsis |
| IL-18 |  |  |  |  |  |  |  |
|  Mommsen, P | 2009 | P-coh | 55 | 23 (42%) |  | Y | (IL-18) is significantly higher in sepsis on days 3-6 post injury |
| IL-1 |  |  |  |  |  |  |  |
|  Menges, T  | 1999 | P-coh  | 68 | 17 (25%) |  | Y | (IL-1) is significantly higher in sepsis and MOF on days 3 + 5 + 6 + 9 - 13 |

P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor; IFN: Interferon; ROC: Receiver operating characteristic; AUC: Area under curve.

**Table 4 Value of cytokine concentrations for predicting muli-organ dysfunction syndrome**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Year** | **Design** | **No pts.** | **MODS*****n* (%)** | **Diagnostic tests**  | **Predicts****MODS** | **Results** |
| IL-6 |  |  |  |  |  |  |  |
|  Cuschieri, J | 2010 | P-coh | 152 | 29 (37%) | > 350 pg/mL: Sensitivity 79%, specificity 76%; OR 3.87 (95%CI: 1.13-11.19) | Y | (IL-6) > 350 pg/mL is highly associated with MODS |
|  Frink, M | 2009 | P-coh | 143 | 24 (17%) | r = 0.35; > 761.7 pg/μL: sensitivity 16.7%, specificity 98.3% | Y | (IL-6) > 76.6 pg/μL is associated with MODS with accuracy of 84.7% |
|  Haasper, C | 2010 | P-coh | 94 | 21 (22%) |  | Y | (IL-6) is significantly higher in MODS on days 1 + 7 |
|  Oberholzer, A | 2000 | P-coh | 1276 | 516 (40%) |  | Y | (IL-6) is significantly higher in (severe) MODS |
|  Sousa, A | 2015 | P-coh | 99 | 34 (34%) | > 294 pg/mL: AUC ROC 0.769 (95%CI: 0.414-0.736) | Y  | (IL-6) > 294 pg/mL is associated with MODS at 48 + 72 h post injury |
| IL-8 |  |  |  |  |  |  |  |
|  Frink, M | 2009 | P-coh | 143 | 24 (17%) | r = 0.53; sensitivity 0% | N | (IL-8) is significantly higher in MODS; does not predict development of MODS |
| IL-10 |  |  |  |  |  |  |  |
|  Frink, M | 2009 | P-coh | 143 | 24 (17%) | r = 0.31; sensitivity 0%  | N | (IL-10) is significantly higher in MODS; does not predict development of MODS  |
|  Neidhardt, R | 1997 | P-cc | 417  | 92 (22%) |  | Y | (IL-10) is significantly higher in MODS on days 1 + 3 + 5 + 7 + 10 + 14 + 21 post injury |
|  Spielmann, S  | 2001 | P-cc | 47  | 24 (51%) |  | N | (IL-10) is not related to the development of MODS |
|  Sousa, A | 2015 | P-coh | 99 | 34 (34%) | > 4.93 pg/mL: AUC ROC 0.700 (95%CI: 0.506-0.841) | Y | (IL-10) > 4.93 pg/mL is associated with MODS at 24 + 72 h post injury |
| TNF- |  |  |  |  |  |  |  |
|  Frink, M | 2009 | P-coh | 143 | 24 (17%) | r = 0.32; sensitivity 0%  | N | (TNF-) is significantly higher in MODS; does not predict development of MODS |
|  Hayakawa, M | 2010 | P-coh | 45 | 24 (53%) |  | Y | (TNF-) is significantly higher in MODS on days 3 + 5 |
|  Sousa, A  | 2015 | P-coh | 99 | 34 (34%) |  | Y | (TNF-) is associated with MODS at 48 h post injury |
|  Spielmann, S | 2001 | P-cc | 47 | 24 (51%) |  | N | (TNF-) is not associated with MODS |
| IL-1β |  |  |  |  |  |  |  |
|  Frink, M  | 2009 | P-coh | 143 | 24 (17%) | r = 0.00; sensitivity 0%  | N | (IL-1β) is not related to development of MODS |
| IL-12 |  |  |  |  |  |  |  |
|  Wick, M | 2000 | P-coh | 37  | 4 (11%) |  | Y | (IL-12) is significantly lower in patients with MODS |
| IL-18 |  |  |  |  |  |  |  |
|  Mommsen, P | 2009 | P-coh | 55 | 7 (13%) |  | Y | (IL-18) is significantly higher in MODS on days 2 + 3 + 6 + 7 + 9 + 10 + 13 + 14 |
| MIF |  |  |  |  |  |  |  |
|  Hayakawa, M | 2010 | P-coh | 45 | 24 (53%) |  | Y | (MIF) is significantly higher in MODS |

P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor; IFN: Interferon; ROC: Receiver operating characteristic; AUC: Area under curve; r: Correlation coefficient between cytokine and development of MODS; MODS: Muli-organ dysfunction syndrome.

**Table 5 Value of cytokine concentrations for predicting multi-organ failure**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Study | **Year** | **Design** | **No pts.** | **MOF*****n* (%)** | **Diagnostic tests**  | **Predicts****MOF** | **Results**  |
| IL-6 |  |  |  |  |  |  |  |
|  Bogner, V | 2009 | P-coh | 58 | 43 (74%) |  | Y | (IL-6) is significantly higher in MOF at 0 - 24 + 72 h |
|  Frank, J | 2002 | P-cc | 77  |  | r = 0.25 on day 2 | N | (IL-6) is significantly higher in MOF; no reliable predictor due to low r |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) | AUC ROC 0.816; (IL-6) > 0.861 pg/mL: Sensitivity 57, PPV 100% | Y | (IL-6) > 0.861 pg/mL is highly predictive for MOF |
|  Lausevic, Z | 2008 | P-coh | 65 | 36 (55%) |  | Y | (IL-6) is significantly higher in MOF on all days of hospitalization |
|  Lendemans, S | 2004 | P-coh | 16  | 9 (56%) |  | Y | (IL-6) is significantly higher in MOF after two weeks |
|  Law, MM | 1994 | P-coh | 13 | 6 (46%) |  | N | (IL-6) is elevated in MOF, does not predict MOF |
|  Maier, B | 2007 | P-coh | 251 | 85 (34%) | AUC ROC 0.70 for late-onset MOF | Y | (IL-6) is predictive for (late) MOF |
|  Partrick, DA | 1996 | P-cc | 27  | 9 (33%) |  | Y | (IL-6) is significantly higher in MOF at 12 + 36 h |
|  Svoboda, P | 1994 | P-cc | 42  | 14 (33%) |  | N | (IL-6) is higher in MOF at day 1, does not predict MOF |
| IL-8 |  |  |  |  |  |  |  |
|  Bogner, V | 2009 | P-coh | 58 | 43 (74%) |  | Y | (IL-8) is significantly higher in MOF from 0-72 h |
|  Frank, J | 2002 | P-cc | 77  |  | r = 0.32 on day 2 | N | (IL-8) is significantly higher in MOF; not reliable due to low r |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) |  | Y | (IL-8) is significantly higher in MOF from 0-24 h |
|  Law, MM | 1994 | P-coh | 13 | 6 (46%) |  | N | (IL-8) is elevated in MOF, does not predict MOF |
|  Maier, B | 2007 | P-coh | 251 | 85 (34%) | AUC ROC 0.69 for late-onset MOF | Y | (IL-8) is predictive for (late) MOF |
|  Partrick, DA | 1996 | P-cc | 27  | 9 (33%) |  | Y | (IL-8) is significantly higher in MOF at 12 + 36 + 84 h  |
| IL-10 |  |  |  |  |  |  |  |
|  Bogner, V | 2009 | P-coh | 58 | 43 (74%) |  | Y | (IL-10) is significantly higher in MOF in early post-injury phase (< 12 h) |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) | AUC ROC 0.776; (IL-10) > 38.6 pg/mL: sensitivity 71%, PPV 77% | Y | (IL-10) > 38.6 pg/mL is predictive for MOF |
|  Lausevic, Z | 2008 | P-coh | 65 | 36 (55%) |  | Y | (IL-10) is significantly higher in MOF in very early post injury phase |
|  Lendemans, S | 2004 | P-coh | 16  | 9 (56%) |  | Y | (IL-10) is significantly higher in MOF on days 3 + 4 |
|  Maier, B | 2007 | P-coh | 251 | 85 (34%) | AUC ROC 0.60 for late-onset MOF | N | (IL-10) is not predictive for MOF |
|  Menges, T  | 1999 | P-coh | 68 | 17 (25%) |  | Y | (IL-10) is significantly higher in sepsis and MOF after 6 d |
| TNF- |  |  |  |  |  |  |  |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) |  | Y | (TNF-) is significantly higher in MOF from 2 – 6 + 10 – 24 h |
|  Lendemans, S | 2004 | P-coh | 16  | 9 (56%) |  | Y | (TNF-) is significantly higher in MOF on days 7 + 8 + 10 + 11 |
|  Menges, T  | 1999 | P-coh | 68 | 17 (25%) |  | Y | (TNF-) is significantly higher in sepsis and MOF after 8 d |
|  Svoboda, P | 1993 | P-cc | 42 | 14 (33%) |  | Y | (TNF-) is higher in MOF, but only after onset of symptoms |
| IL-1(β) |  |  |  |  |  |  |  |
|  Menges, T  | 1999 | P-coh | 68 | 17 (25%) |  | Y | (IL-1) is significantly higher in sepsis and MOF on days 3 + 5 + 6 + 9 - 13 |
|  Svoboda, P | 1994 | P-xx | 42 | 14 (33%) |  | N | (IL-1β) is not related to MOF |
| IL-2 |  |  |  |  |  |  |  |
|  Svoboda, P | 1994 | P-cc | 42 | 14 (33%) |  | N | (IL-2) is not related to MOF |
| IP-10 |  |  |  |  |  |  |  |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) | > 889.9 pg/mL has a sensitivity of 71% and PPV of 100% | Y | (IP-10) is highly predictive for MOF (AUC ROC 0.939) |
| Eotaxin |  |  |  |  |  |  |  |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) | > 193.8 pg/mL has a sensitivity of 71% and PPV of 62% | Y | (Eotaxin) is highly predictive for MOF (AUC ROC 0.810) |
| MIP-1β |  |  |  |  |  |  |  |
|  Jastrow, KM | 2009 | P-coh | 48 | 11 (23%) | > 248.6 pg/mL has a sensitivity of 71% and PPV of 77% | Y | (MIP-1β) is highly predictive for MOF (AUC ROC 0.871) |
| IL-11 |  |  |  |  |  |  |  |
|  Schinkel, C | 2005 | P-cc | 216 | 9 (4%) |  | N  | (IL-11) is not significantly different in MOF |

P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor; IFN: Interferon; ROC: Receiver operating characteristic; AUC: Area under curve; r: Correlation coefficient between cytokine and development of MOF;PPV: Positive predictive value; MOF: Multi-organ failure.

**Table 6 Value of cytokine concentrations for predicting mortality**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Design** | **No pts.** | **Mortality *n* (%)** | **Follow-up** | **Diagnostic tests** | **Predicts mortality** | **Results**  |
| IL-6 |  |  |  |  |  |  |  |
|  Bogner, V | P-coh | 58 | 11 (19%) | 90 d |  | Y | (IL-6) is significantly higher in non-survivors at 0 + 6 h |
|  Cuschieri, J | P-coh | 152 | 4 (5%) | In-hospital |  | N | (IL-6) is not significantly higher in non-survivors |
|  Dresing, K | P-coh | 30 | 6 (19%) | 29 d  |  | Y | (IL-6) is significantly higher in non-survivors on days 3 + 5 |
|  Frink, M | P-coh | 143 | 21 (15%) | In-hospital | > 2176.0 pg/mL: Sensitivity 28.6%, specificity 100% on day 1 | Y | (IL-6) is highly predictive for non-survival (AUC ROC 0.858) |
|  Frangen, TM | P-cc | 71  | 16 (22%) | In-hospital  |  | Y | (IL-6) is significantly higher in non-survivors |
|  Gebhard, F | P-coh | 94 | 18 (19%) | In-hospital |  | Y | (IL-6) is significantly higher in non-survivors at 4 + 6 + 12 h post injury |
|  Maier, B | P-coh | 251 | 29 (12%) | In-hospital | AUC ROC 0.60 | N | (IL-6) is not predictive for non-survival |
|  Sousa, A | P-coh | 99 | 28 (28%) | 72 h | > 276 pg/mL: AUC ROC2 0,775 (95%CI: 0.591-0.960) | Y | (IL-6) > 276 pg/mL is significantly correlated with non-survival |
|  Svoboda, P | P-cc | 42 | 11 (26%) | In-hospital | > 400 pg/mL has a sensitivity of 100%  | Y | (IL-6) > 400 pg/mL is significantly correlated with non-survival |
|  Yagmur, Y | P-cc | 99  | 17 (17%) | 60 d  |  | Y | (IL-6) is significantly elevated in non-survivors |
| IL-8 |  |  |  |  |  |  |  |
|  Bogner, V | P-coh | 58 | 11 (19%) | 90 d |  | Y | (IL-8) is significantly higher in non-survivors at 6 + 24 h |
|  Liener, UC | P-coh | 94 | 18 (19%) | 15 d  |  | Y | (IL-8) is significantly higher in non-survivors from 30 min-24 h |
|  Maier, B | P-coh | 251 | 29 (12%) | In-hospital | AUC ROC 0.45 | N | (IL-8) is not predictive for non-survival |
|  Yagmur, Y | P-cc | 99  | 17 (17%) | 60 d  |  | Y | (IL-8) is significantly elevated in non-survivors |
| IL-10 |  |  |  |  |  |  |  |
|  Bogner, V | P-coh | 58 | 11 (19%) | 90 d |  | Y | (IL-10) is significantly higher in non-survivors at 72 h post injury  |
|  Gouel-Geron, A | P-cc | 100  | 5 (5%) | 14 d  |  | Y | (IL-10) is significantly higher in non-survivors when detectable on days 1 + 2  |
|  Heizmann, O | R-cc | 195  | 37 (19%) | 42 d  |  | N | (IL-10) tends towards lower levels in non-survivors; not significant |
|  Maier, B | P-coh | 251 | 29 (12%) | In-hospital | AUC ROC 0.51 | N | (IL-10) is not predictive for non-survival |
|  Neidhardt, R | P-cc | 417  | 92 (22%) | 21 d  |  | Y | (IL-10) is significantly increased in non-survivors on days 1 + 3 |
|  Sherry, RM | R-cc | 66  | 1 (2%) | 50 d  |  | N | (IL-10) is not related to non-survival |
|  Sousa, A | P-coh | 99 | 28 (28%) | 72 h  | > 8.24 pg/mL: AUC ROC 0.871 (95%CI: 0.715-1.000) | Y | (IL-10) > 8.24 pg/mL is associated with non-survival at 48 + 72 h post injury |
| TNF- |  |  |  |  |  |  |  |
|  Dresing, K | P-coh | 30 | 6 (19%) | 29 d  |  | N | (TNF-) is not significantly elevated in non-survivors |
|  Sousa, A  | P-coh | 99 | 28 (28%) | 72 h  |  | N | (TNF-) is not significantly elevated in non-survivors |
|  Spielmann, S | P-cc | 47  | 11 (23%) | 6 d  |  | N  | (TNF-) is not significantly elevated in non-survivors |
|  Svoboda, P | P-cc | 42 | 11 (26%) | In-hospital |  | Y | (TNF-) is significantly elevated in non-survivors |
|  Yagmur, Y | P-cc | 99  | 17 (17%) | 60 d  |  | N | (TNF-) is not significantly elevated in non-survivors |
| IL-18 |  |  |  |  |  |  |  |
|  Heizmann, O | R-cc | 195  | 37 (19%) | 42 d  |  | N | (IL-18) tends towards lower levels in non-survivors; not significant |
|  Mommsen, P  | P-coh | 55 | 7 (13%) | 14 d  |  | Y | (IL-18) is significantly increased in non-survivors on days 2-7 |
|  Roetman, B | P-cc | 229  | 36 (16%) | 30 d  |  | N | (IL-18) median value is significantly lower in non-survivors |
| IL-2 |  |  |  |  |  |  |  |
|  Heizmann, O | R-cc | 195 | 37 (19%) | 42 d  |  | N | (IL-2) tends towards lower levels in non-survivors; not significant |
|  Svoboda, P | P-cc | 42  | 11 (26%) | In-hospital |  | N | (IL-2) is not related to non-survival |
|  Yagmur,  | P-cc | 99  | 17 (17%) | 60 d  |  | Y | (IL-2) is significantly increased in non-survivors |
| IL-1 |  |  |  |  |  |  |  |
|  Svoboda, P | P-cc | 42  | 11 (26%) | In-hospital |  | N | (IL-1) is not related to non-survival |
|  Yagmur, Y | P-cc | 99  | 17 (17%) | 60 d  |  | N | (IL-1) is not related to non-survival |
| IL-12 |  |  |  |  |  |  |  |
|  Heizmann, O | R-cc | 195  | 37 (19%) | 42 d  |  | N | (IL-12) tends towards lower levels in non-survivors; not significant |
|  Wick, M | P-coh | 37  | 6 (16%) | In-hospital |  | Y | (IL-12) is significantly lower in non-survivors |
| IL-11 |  |  |  |  |  |  |  |
|  Schinkel, C | P-cc | 216  | 34 (16%) | In-hospital |  | N | (IL-11) is lower in non-survivors, only reaching significance after week 4 |
|  Heizmann, O | R-cc | 195  | 37 (19%) | 42 d  |  | N | (IL-11) tends towards lower levels in non-survivors; not significant |
| IL-17 |  |  |  |  |  |  |  |
|  Frangen, TM | P-cc | 71  | 16 (22%) | In-hospital |  | N | (IL-17) is not related to non-survival |
| IL-4 |  |  |  |  |  |  |  |
|  Heizmann, O | R-cc | 195  | 37 (19%) | 42 d  |  | N | (IL-4) tends towards lower levels in non-survivors; not significant |
|  Roetman, B  | P-cc | 229 | 36 (16%) | 30 d  |  | N | (IL-4) is not related to mortality |
| IFN-γ |  |  |  |  |  |  |  |
|  Heizmann, O | R-cc | 195  | 37 (19%) | 42 d  |  | N | (IFN-γ) tends towards lower levels in non-survivors; not significant |
|  Roetman, B  | P-cc | 229 | 36 (16%) | 30 d  |  | N  | (IFN-γ) inconsistently detectable |

P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor; IFN: Interferon;AUC: Area under the receiver operating characteristic (ROC) curve.